Sakura Bio

Sakura Bio is a private Israeli cell therapy company developing next-generation T- and NK-cell therapies for cancer. Its core platform, T-Boost, is designed to reprogram T and NK cells during manufacturing to improve potency, persistence, and resistance to the tumor microenvironment, and the company positions it as a modular plug-in technology compatible with CAR-T, TCR-T, CAR-NK, TILs, and related approaches. Sakura Bio has also described an off-the-shelf allogeneic T-cell product called Skill-T or SAK (Super Activated Killer T cells), with acute myeloid leukemia identified in external company profiles as an initial indication. The company appears to be at the preclinical or R&D stage, with messaging focused on generating more effective, durable, and accessible cellular immunotherapies.